Open AccessAntithymocyte Globulin Versus Interleukin-2 Receptor Antagonist in Kidney Transplant Recipients With Hepatitis C Virus
Author(s) -
Sunjae Bae,
Christine M. Durand,
Jacqueline Garonzik-Wang,
Eugene M. Chow,
Lauren M. Kucirka,
Mara McAdamsDeMarco,
Allan B. Massie,
Fawaz Al Ammary,
Josef Coresh,
Dorry L. Segev
Publication year - 2020
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/tp.0000000000002959
Subject(s) - medicine , hepatitis c virus , hazard ratio , odds ratio , gastroenterology , hepatitis c , population , cirrhosis , immunology , liver transplantation , kidney transplantation , proportional hazards model , transplantation , confidence interval , virus , environmental health
Hepatitis C virus-positive (HCV+) kidney transplant (KT) recipients are at increased risks of rejection and graft failure. The optimal induction agent for this population remains controversial, particularly regarding concerns that antithymocyte globulin (ATG) might increase HCV-related complications.